
Vishwanath S Gharpure MD FACP
Senior Clinical Trial Physician, Bristol Myers Squibb
Join to view full profile
14 Blossom Hill DrivePlainsboro, NJ 08536
Phone+1 609-436-0363
Dr. Gharpure is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Texas Health Resources (Dallas)Residency, Internal Medicine, 1997 - 1998
Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1994 - 1996
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 1993 - 1994
University of MarylandFellowship, Hematology and Medical Oncology, 1990 - 1993
Seth G.S. Medical CollegeClass of 1983
Certifications & Licensure
NJ State Medical License 1998 - 2027
PA State Medical License 1999 - 2026
IN State Medical License 1994 - 2019
TX State Medical License 1998 - 1999
MD State Medical License 1993 - 1994
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ, Elekta - IMPAC Medical Systems, Inc., 2013, 2015-2017
- CMS Meaningful Use Stage 1 Certification Patient Engagement Portal, Navigating Cancer, Inc., 2013, 2015-2017
- CMS Meaningful Use Stage 2 Certification OncoEMR by Flatiron Health, Flatiron Health, Inc., 2013, 2015-2017
Publications & Presentations
PubMed
- TIGOS Trial: A Randomized, Double-Blind, Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as ...Luis G Paz-Ares, Kenneth John O'Byrne, Melissa L Johnson, Martin Reck, Nicolas Girard
Clinical Lung Cancer. 2026-03-01 - 25 citationsNeoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.Mark M Awad, Patrick M Forde, Nicolas Girard, Jonathan Spicer, Changli Wang
Journal of Clinical Oncology. 2025-04-20
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









